BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/12/2014 11:15:00 AM | Browse: 1097 | Download: 1145
Publication Name World Journal of Pharmacology
Manuscript ID 12854
Country/Territory Italy
Received
2014-07-28 08:46
Peer-Review Started
2014-07-28 19:02
To Make the First Decision
2014-08-14 14:34
Return for Revision
2014-08-18 11:36
Revised
2014-08-29 04:53
Second Decision
2014-09-24 16:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-09-24 16:24
Articles in Press
2014-09-24 16:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-28 17:55
Publish the Manuscript Online
2014-12-12 11:14
ISSN 2220-3192 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Nanoscience & Nanotechnology
Manuscript Type Review
Article Title Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?
Manuscript Source Invited Manuscript
All Author List Serena Mazzucchelli, Marta Truffi, Luisa Fiandra, Luca Sorrentino and Fabio Corsi
Funding Agency and Grant Number
Corresponding Author Fabio Corsi, MD, Professor, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, via G. B. Grassi, 74, 20157 Milan, Italy. fabio.corsi@unimi.it
Key Words Human epidermal growth factor receptor 2; Human epidermal growth factor receptor 2+-breast cancer; Nanomedicine; Nanoparticle; Targeted-therapy
Core Tip About 30% of human breast cancers are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) receptor, which determines the deregulation of cell survival and proliferation pathways. The HER2-targeted therapy is the most effective treatment, despite some related limitations, which could be bypassed with the development of nanoparticles for HER2-targeted drug delivery, photothermal ablation or photodynamic therapy. Here, we describe HER2+ breast cancer features and anti-HER2 therapy, and focus on the contribution of nanomedicine in this context, by reporting HER2-targeted nanoparticles under preclinical investigations. Promising results suggest upcoming clinical application of these nano-compounds in the next future.
Publish Date 2014-12-12 11:14
Citation Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85
URL http://www.wjgnet.com/2220-3192/full/v3/i4/72.htm
DOI http://dx.doi.org/10.5497/wjp.v3.i4.72
Full Article (PDF) WJP-3-72.pdf
Full Article (Word) WJP-3-72.doc
Manuscript File 12854-Review.docx
Answering Reviewers 12854-Answering reviewers.pdf
Copyright License Agreement 12854-Copyright assignment.pdf
Peer-review Report 12854-Peer review(s).pdf
Scientific Misconduct Check 12854-CrossCheck.jpg
Scientific Editor Work List 12854-Scientific editor work list.pdf